Cognition Therapeutics secures patent extension for lead candidate

Cognition Therapeutics has been granted a new composition of matter patent for its lead candidate, Zervimesine (CT1812). This patent extends protection through 2045, providing significant market exclusivity for the drug. The company, a clinical-stage entity, focuses on developing treatments for neurodegenerative diseases. This extended patent life is crucial for recouping research and development investments and fostering further innovation in the pharmaceutical sector. Investors will be watching the clinical trial progress closely.